• Luis Jesús Jiménez-Borreguero, Servicio de Cardiología del Hospital de la Princesa y Centro Nacional de Investigaciones Cardiovasculares, Madrid

• Marisa Toribio, Centro de Biología Molecular Servero Ochoa, CSIC, Madrid

• Manuel Fresno , Centro de Biología Molecular “Severo Ochoa” (CSIC), Madrid

• Carlos Ardavín, Centro Nacional de Biotecnología (CSIC). Madrid

• Ana Urzainqui, Departamento de Inmunología. Hospital Universitario de la Princesa (Madrid)

• Pilar Martín
• Junior group leader
• Ext.2009

María Pilar Martín Fernández (Madrid, 1973) has a degree in Biological Sciences at the Complutense University of Madrid (1996), where she did her doctoral thesis in immunology (2001). During her PhD, under the supervision of C. Ardavín, she studied the immune response against the Mouse Mammary Tumour Virus (MMTV) in collaboration with Dr. Hans Acha-Orbea from Ludwig Institute of Cancer Research (Laussane, Switzerland). This work was carried out in parallel to the characterization of the different Dendritic cells subpopulations in mice and the study of their origin/lineage. In the postdoctoral stage she moved to the laboratory of Dr. J. Moscat at the Centro de Biología Molecular “Severo Ochoa” where she obtained an I3P postdoctoral contract from CSIC. Her work focused in the characterization of , the inhibitor Par-4 and the deficient mice for the atypical protein kinase PKC? scaffold protein p62. The development of chronic inflammatory disease animal models (allergic asthma, ulcerative colitis, rheumatoid arthritis, EAE…) in collaboration with Dr. Paul Rennert from Biogen Inc, (Cambridge, Boston, USA), signalling is necessary for IL-4 activation pathway helped to show that PKC? (Jak-1/Stat-6) in vitro and in vivo, and therefore, essential for the differentiation of Th2 cells. In january 2007, she joined to Dr. F. Sánchez-Madrid (Hospital Universitario de la Princesa) lab with a Ramón y Cajal contract and later she moved to the Dept. Vascular Biology and Inflammation (CNIC) as a Junior I Researcher, where she develops and independent line of investigation focusing on the study of regulatory molecules in inflammatory processes.